Review article:: impact of Helicobacter pylori on society -: role for a strategy of 'search and eradicate'

被引:26
作者
Forman, D [1 ]
Graham, DY
机构
[1] Univ Leeds, Sch Med, Unit Epidemiol & Hlth Serv Res, Leeds LS16 6QB, W Yorkshire, England
[2] Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA
[3] Baylor Coll Med, Houston, TX 77030 USA
关键词
D O I
10.1111/j.0953-0673.2004.01831.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Helicobacter pylori infection is causally related to gastric cancer, a malignancy associated with high morbidity and poor prognosis. and to peptic ulcer disease, a disease with high morbidity and modest mortality. Theoretically, H. pylori eradication is the most practical means of preventing gastric cancer and peptic ulcer disease. From a public policy perspective. the current evidence is insufficient to assess accurately the magnitude of the benefits of a universal 'search and treat' approach. Nonetheless. it is possible to identify high-risk patients for whom testing for the presence of H. pylori infection, with the intention-to-treat infected individuals is currently indicated. This list includes patients with ulcers or dyspepsia. first-degree relatives of patients with peptic ulcer or gastric cancer, gastric cancer patients after potentially curative resection of their gastric cancer, patients in whom long-term acid antisecretory therapy or long-term nonsteroidal anti-inflammatory drug therapy (including low-dose aspirin) is planned, and finally those who desire testing. Population screening among asymptomatic individuals with a high risk of gastric cancer, such as Korean- and Japanese-Americans, appears logical, but from a public health perspective should be done as a component of controlled intervention studies. There arc no known H. pylori infections without risk of a symptomatic outcome, therefore screening represents a rational strategy for cancer prevention. Adoption of such a policy will require carefully balancing the costs of the programme with its benefits.
引用
收藏
页码:17 / 21
页数:5
相关论文
共 37 条
[1]  
Aldana LP, 2002, HELICOBACTER, V7, P306
[2]  
*AM CANC SOC, WHAT AR KEY STAT STO
[3]  
[Anonymous], LANCET
[4]  
[Anonymous], IARC MON PROGR EV CA
[5]  
Axon Anthony, 2003, Can J Gastroenterol, V17 Suppl B, p62B
[6]  
BERRINO F, 1999, IARC SCI PUBLICATION, V151
[7]  
BORODY TJ, 1993, AM J GASTROENTEROL, V88, P1266
[8]  
Breuer Thomas, 1997, P1
[9]   Chemoprevention of gastric dysplasia:: Randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy [J].
Correa, P ;
Fontham, ETH ;
Bravo, JC ;
Bravo, LE ;
Ruiz, B ;
Zarama, G ;
Realpe, JL ;
Malcom, GT ;
Li, D ;
Johnson, WD ;
Mera, R .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (23) :1881-1888
[10]  
CORREA P, 1992, CANCER RES, V52, P6735